Meetings - The ASCO Post

/ ESMO Congress 2026

Brian M. Slomovitz, MD, on dMMR Advanced or Recurrent Endometrial Cancer: KEYNOTE-C93/GOG-3064/ENGOT-en15

Brian M. Slomovitz, MD, of Mount Sinai Medical Center, discusses results from a phase III, randomized, open-label study of first-line pembrolizumab vs carboplatin/paclitaxel in patients with mismatch ...

Prostate Cancer

By The ASCO Post Staff / October 2026 / ESMO Congress 2026

Triplet Therapy With Abiraterone Improves Long-Term OS in Metastatic Castration-Sensitive Prostate Cancer

Abiraterone acetate added to androgen-deprivation therapy and docetaxel resulted in a significant overall survival benefit compared with standard-of-care therapy alone in patients with de novo metasta...

Skin Cancer

By The ASCO Post Staff / October 2026 / ESMO Congress 2026

High-Risk Melanoma: Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery

Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-...

ESMO Congress 2026

Brian M. Slomovitz, MD, on dMMR Advanced or Recurrent Endometrial Cancer: KEYNOTE-C93/GOG-3064/ENGOT-en15

Triplet Therapy With Abiraterone Improves Long-Term OS in Metastatic Castration-Sensitive Prostate Cancer

High-Risk Melanoma: Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery

High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery

GLP-1 RA Use Lower Among Adults With Both Diabetes and a History of Cancer

Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sezary Syndrome

FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors